Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Sector Analysis

Pharmaceutical Preparations

Standard Industrial Classification: SIC 2834

Industry Insider Sentiment Analysis

The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.

Filing Date Trade Date Ticker Company Reporting Person Relationship Type Price Qty Total, $ Owned After
2026-11-19 21:05 2026-11-17 AVLN Avalyn Pharma Inc. Carlson Douglas R Officer OPT+S $27.90 14,875 $414,983 0
2026-11-19 21:05 2026-11-17 AVLN Avalyn Pharma Inc. Rhodes Melissa Officer OPT+S $27.90 13,300 $371,046 0
2026-11-19 21:05 2026-11-17 AVLN Avalyn Pharma Inc. Baranowski Lyn Director, Officer OPT+S $27.84 52,500 $1,461,458 0
2026-11-19 19:02 2026-11-17 PRTA PROTHENA CORP PUBLIC LTD CO SCULLY WILLIAM P 10% owner BUY $8.09 50,000 $404,680 1,027,000
2026-11-19 19:09 2026-11-17 CVSI CV Sciences, Inc. CHEEVER CHARLIE E III 10% owner BUY $0.01 2,030,711 $20,307 34,120,348
2026-11-19 17:35 2026-11-18 CLNN Clene Inc. WILCOX REED N Director BUY $3.42 10,000 $34,240 38,756
2026-11-19 13:30 2026-11-18 CATX Perspective Therapeutics, Inc. Williamson Robert F III Director BUY $0.80 15,000 $12,000 68,473
2026-11-18 21:13 2026-11-16 RPRX Royalty Pharma plc Urist Marshall Officer SELL $69.50 25,000 $1,737,490 125,000
2026-11-18 21:14 2026-11-16 RPRX Royalty Pharma plc Coyne Terrance P. Officer SELL $68.81 257,122 $17,693,645 0
2026-11-18 21:15 2026-11-17 RPRX Royalty Pharma plc Hite Christopher Officer SELL $68.15 100,000 $6,814,710 177,523
2026-11-18 21:27 2026-11-16 VRTX VERTEX PHARMACEUTICALS INC / MA Thornberry Nancy Director SELL $547.86 1,000 $547,860 1,109
2026-11-18 21:13 2026-11-16 ARQT Arcutis Biotherapeutics, Inc. Welgus Howard G. Director OPT+S $28.16 4,728 $133,140 34,573
2026-11-18 21:10 2026-11-16 REGN REGENERON PHARMACEUTICALS, INC. McCourt Marion Officer SELL $960.25 566 $543,504 10,305
2026-11-18 21:25 2026-11-16 VRTX VERTEX PHARMACEUTICALS INC / MA Bhatia Sangeeta N. Director SELL $547.86 271 $148,470 4,653
2026-11-18 21:30 2026-11-16 LRMR Larimar Therapeutics, Inc. Clayton Russell Officer BUY $3.01 3,322 $9,999 74,765
2026-11-18 21:11 2026-11-16 AMPH Amphastar Pharmaceuticals, Inc. PETERS WILLIAM J Director, Officer OPT+S $29.99 11,000 $329,890 167,076
2026-11-18 21:00 2026-11-17 LITS Lite Strategy, Inc. Flynn James P Director BUY $0.79 27,450 $21,548 152,450
2026-11-18 21:13 2026-11-16 REGN REGENERON PHARMACEUTICALS, INC. SING GEORGE L Director SELL $958.97 2,000 $1,917,945 23,147
2026-11-18 21:13 2026-11-16 FLNA FILANA THERAPEUTICS, INC. Barry Richard Director, Officer BUY $0.47 440,206 $206,897 1,778,170
2026-11-18 21:11 2026-11-16 FLNA FILANA THERAPEUTICS, INC. Schoen Eric Officer BUY $0.42 20,000 $8,400 31,500
2026-11-19 01:59 2026-11-16 AVIR Atea Pharmaceuticals, Inc. Polsky Bruce Director OPT+S $4.08 41,226 $168,095 158,580
2026-11-19 01:32 2026-11-16 ANIP ANI PHARMACEUTICALS INC Lalwani Nikhil Director, Officer SELL $71.22 5,400 $384,580 328,289
2026-11-19 01:35 2026-11-16 GRCE Grace Therapeutics, Inc. Opaleye Management Inc. 10% owner BUY $1.74 48,060 $83,437 3,102,904
2026-11-19 00:32 2026-11-16 ANRO Alto Neuroscience, Inc. Hanley Jr. Michael Conick Officer OPT+S $27.61 75,000 $2,070,390 0
2026-11-19 00:12 2026-11-16 CYTK CYTOKINETICS INC Blum Robert I Director, Officer OPT+S $53.53 7,500 $401,460 278,544
2026-11-18 23:56 2026-11-16 ANAB ANAPTYSBIO, INC EcoR1 Capital, LLC Director, 10% owner BUY $45.98 374,580 $17,224,574 8,254,674
2026-11-18 23:58 2026-11-17 CYTK CYTOKINETICS INC Malik Fady Ibraham Officer OPT+S $51.78 3,500 $181,227 153,902
2026-11-18 23:59 2026-11-18 BIVI BIOVIE INC. DO CUONG V Director, Officer BUY $1.00 2,500 $2,493 21,117
2026-11-19 00:00 2026-11-16 SEPN Septerna, Inc. Labrucherie Gil M Officer SELL $41.62 20,000 $832,360 20,000
2026-11-18 23:49 2026-11-17 CYTK CYTOKINETICS INC Hessekiel Jeffrey Officer SELL $52.62 15,106 $794,878 92,837
2026-11-18 23:04 2026-11-16 ROIV Roivant Sciences Ltd. Gold Daniel Allen Director SELL $38.75 1,381,762 $53,536,783 5,805,461
2026-11-18 23:08 2026-11-16 ROIV Roivant Sciences Ltd. MANCHESTER KEITH S Director SELL $38.75 1,381,762 $53,536,783 5,805,461
2026-11-18 22:29 2026-11-16 ROIV Roivant Sciences Ltd. QVT Financial LP SELL $38.75 1,381,762 $53,536,783 5,805,461
2026-11-18 22:32 2026-11-16 EWTX Edgewise Therapeutics, Inc. Donovan Joanne M. Officer SELL $45.48 854 $38,840 8,139
2026-11-18 22:20 2026-11-16 PTCT PTC THERAPEUTICS, INC. Boulding Mark Elliott Officer OPT+S $61.88 2,812 $174,013 105,272
2026-11-18 22:21 2026-11-16 CRMD CorMedix Inc. Kaplan Myron Director BUY $4.88 25,000 $122,000 256,487
2026-11-18 22:08 2026-11-17 RYTM RHYTHM PHARMACEUTICALS, INC. JEAN CHRISTOPHE Director OPT+S $109.66 10,000 $1,096,550 11,712
2026-11-18 21:41 2026-11-17 UTHR UNITED THERAPEUTICS Corp ROTHBLATT MARTINE A Director, Officer OPT+S $580.43 9,500 $5,514,046 324,443
2026-11-18 21:36 2026-11-17 ASND Ascendis Pharma A/S PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG Officer OPT+S $263.89 20,000 $5,277,720 19,460
2026-11-18 21:05 2026-11-16 IRWD IRONWOOD PHARMACEUTICALS INC Gaskins Tammi L Officer SELL $4.81 5,919 $28,470 344,431
2026-11-18 21:05 2026-11-16 KURA Kura Oncology, Inc. FORD KATHLEEN Officer SELL $7.45 10,710 $79,755 132,276
2026-11-18 21:05 2026-11-16 KURA Kura Oncology, Inc. Bair Teresa Brophy Officer SELL $7.44 8,601 $63,991 178,401
2026-11-18 21:05 2026-11-16 KURA Kura Oncology, Inc. Powl Brian T. Officer SELL $7.45 24,450 $182,060 113,265
2026-11-18 21:05 2026-11-16 KURA Kura Oncology, Inc. Leoni Mollie Officer SELL $7.45 41,250 $307,123 99,845
2026-11-18 21:05 2026-11-16 KURA Kura Oncology, Inc. DOYLE THOMAS JAMES Officer SELL $7.44 4,697 $34,946 138,081
2026-11-18 21:05 2026-11-16 FLNA FILANA THERAPEUTICS, INC. Cook Robert Christopher Officer BUY $0.46 121,575 $55,925 135,300
2026-11-18 21:07 2026-11-17 REGN REGENERON PHARMACEUTICALS, INC. MURPHY ANDREW J Officer OPT+S $957.76 5,011 $4,799,336 46,779
2026-11-18 21:08 2026-11-18 ALT Altimmune, Inc. MENZIUSO RICHARD THOMAS Officer BUY $1.42 10,000 $14,187 10,000
2026-11-18 20:18 2026-11-18 ZYME Zymeworks Inc. Platshon Scott Officer OPT+S $24.95 15,292 $381,535 21,745
2026-11-18 13:20 2026-11-17 CATX Perspective Therapeutics, Inc. Williamson Robert F III Director BUY $0.84 25,000 $20,950 53,473
SHOW ENTRIES

Sector-Wide Insider Alpha

Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.

SEC Filings in Pharmaceutical Preparations

Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.